A leading German pharmaceutical cannabis company specializing in GDP/EU-GMP-certified import, manufacturing, and wholesale is seeking a strategic equity partner to invest €1 million. This partnership will support expansion into telehealth, new markets, and further growth opportunities.
Key Highlights:
- Operations: Specializes in pharmaceutical-grade medical cannabis products, adhering to EU-GMP and GDP standards. Operates an asset-light model, leveraging an experienced pharmaceutical logistics partner for warehousing and distribution.
- Supply Chain: Sources high-quality products from trusted cultivators and extraction facilities in Portugal, Spain, Denmark, and Canada, ensuring rapid market entry through regulatory expertise.
- Customer Base: Serves over 700 pharmacies in Germany with a dedicated sales team and established supply agreements with major global cannabis players.
- Growth & Expansion: Plans to enter new markets, such as Portugal, via joint ventures with local cultivators. Developing a telemedicine platform to enhance profitability and market reach by 2025.
- Financial Performance: Generated €800k in revenue in 2023, with projections of €1.5 million in 2024 and profitability expected by Q1 2025. Company valued at €5 million pre-investment.
Investment Opportunity:
- Seeking €1 million for product expansion, securing exclusive contracts, increasing sales, and entering the Portuguese market.
- Open to discussions for a majority takeover (51%+ ownership).
This is an opportunity to partner with a well-positioned cannabis company in the growing European pharmaceutical market, that has expertise in regulatory compliance, strategic partnerships, and innovative growth initiatives.
